Idiopathic Pulmonary Fibrosis (IPF) is a condition in which the tissue of the lungs has become thick and scarred, usually because of inflammation caused by different lung conditions. Currently, clinicians do not have an available treatment for this disease.
Biotherapix maintains a co-development program with Digna Biotech to evaluate the combined therapeutic effect of Btx201 and p17 in the treatment of IPF. The complementarity of both molecules in their action against the fibrotic process is this program's key innovation.
Btx201
acts in the early stage of inflammation
p17
acts in later stage of inflammation
Murine herpes-derived protein that acts as a broad–spectrum chemokine inhibitor
The selective chemokine binding profile of Btx201 has proved to be of therapeutic utility in several murine inflammatory disease models.
Inhibitory peptide for transforming growth factor beta (TFG-ß1)
p17 has shown a dose dependent antifibrotic effect in various models including pulmonary fibrosis induced by bleomycin in vivo
